IQVIA Holdings Inc. $IQV Shares Sold by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 26.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,325 shares of the medical research company’s stock after selling 4,745 shares during the quarter. New Age Alpha Advisors LLC’s holdings in IQVIA were worth $3,004,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in IQVIA during the 3rd quarter valued at $14,278,000. Eagle Rock Investment Company LLC grew its holdings in IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd acquired a new stake in IQVIA during the 3rd quarter valued at $4,008,000. EDENTREE ASSET MANAGEMENT Ltd purchased a new position in shares of IQVIA during the 3rd quarter worth $7,368,000. Finally, AMG National Trust Bank purchased a new position in shares of IQVIA during the 3rd quarter worth $3,713,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on IQV shares. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Morgan Stanley set a $225.00 price target on IQVIA in a research note on Thursday, May 7th. Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. Finally, Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Buy” and a consensus target price of $225.69.

IQVIA Price Performance

Shares of IQVIA stock opened at $161.94 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $136.41 and a twelve month high of $247.04. The stock has a market capitalization of $27.03 billion, a P/E ratio of 20.07, a PEG ratio of 1.61 and a beta of 1.18. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s fifty day moving average price is $169.78 and its 200 day moving average price is $196.80.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the firm earned $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.